Renal effects of temocapril hydrochloride (CS-622) in patients with benign nephrosclerosis

SUMMARY: The short-term effects of temocapril, a new angiotensin-converting enzyme inhibitor (ACE-I), on renal function were investigated in 10 patients with benign nephrosclerosis (56.2 ± 7.2 years, mean ± SD). Renal plasma flow and glomerular filtration rate (GFR) were examined before and after 12-week administration, using ¹³¹I-hippuran and ^99mTc-DTPA, respectively. Temocapril (mean 4.5 mg/day) decreased systolic and diastolic blood pressure (from 162 ± 6 to 140 ± 12 mmHg, P <0.001, and from 101 ± 5 to 89 ± 8 mmHg, P <0.001, respectively). Temocapril increased both renal plasma flow (from 323 ± 67 to 367 ± 72 mL/min/1.73 m² P <0.05) and GFR (from 74 ± 14 to 81 ± 15 mL/min/1.73 m², P <0.05). These data show that short-term administration of temocapril improves renal function in patients with benign nephrosclerosis.